United Therapeutics Corporation Cash Flow Conversion Efficiency
United Therapeutics Corporation cash flow conversion efficiency. Based on the latest financial reports, United Therapeutics Corporation (UTHR) has a cash flow conversion efficiency ratio of 0.049x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($313.60 Million) by net assets ($6.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of United Therapeutics Corporation (1998–2025)
Cash flow conversion efficiency of United Therapeutics Corporation from 1998 to 2025. This chart illustrates how United Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View UTHR stock price and chart for real-time trading data and today's change.
United Therapeutics Corporation Cash Flow Conversion Ratio Explained
United Therapeutics Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
United Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of United Therapeutics Corporation ranked by their cash flow conversion efficiency. Also see UTHR stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hindalco Industries Limited
NSE:HINDALCO
|
0.060x |
|
Coca-Cola Femsa SAB de CV ADR
NYSE:KOF
|
0.078x |
|
Eicher Motors Limited
NSE:EICHERMOT
|
0.120x |
|
International Flavors & Fragrances Inc
NYSE:IFF
|
0.030x |
|
Baidu Inc
NASDAQ:BIDU
|
0.009x |
|
Santos Ltd
AU:STO
|
0.072x |
|
Kuehne & Nagel
SW:KNIN
|
0.210x |
|
Equifax Inc
NYSE:EFX
|
0.052x |
Annual Cash Flow Conversion Efficiency for United Therapeutics Corporation (1998–2025)
The table below shows the annual cash flow conversion efficiency of United Therapeutics Corporation from 1998 to 2025. Review cash generation quality of United Therapeutics Corporation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.10 Billion | $1.56 Billion | 0.220x | +6.83% |
| 2024-12-31 | $6.44 Billion | $1.33 Billion | 0.206x | +26.03% |
| 2023-12-31 | $5.98 Billion | $978.00 Million | 0.163x | -2.32% |
| 2022-12-31 | $4.80 Billion | $802.50 Million | 0.167x | +10.72% |
| 2021-12-31 | $3.96 Billion | $598.20 Million | 0.151x | -32.11% |
| 2020-12-31 | $3.40 Billion | $755.70 Million | 0.223x | +399.54% |
| 2019-12-31 | $2.78 Billion | $-206.60 Million | -0.074x | -126.62% |
| 2018-12-31 | $2.79 Billion | $778.40 Million | 0.279x | +23.72% |
| 2017-12-31 | $2.10 Billion | $474.20 Million | 0.226x | -34.72% |
| 2016-12-31 | $1.86 Billion | $643.60 Million | 0.346x | +44.42% |
| 2015-12-31 | $1.60 Billion | $382.80 Million | 0.239x | -14.76% |
| 2014-12-31 | $1.27 Billion | $355.30 Million | 0.281x | -13.90% |
| 2013-12-31 | $1.30 Billion | $425.27 Million | 0.326x | +10.30% |
| 2012-12-31 | $1.09 Billion | $323.63 Million | 0.296x | +12.06% |
| 2011-12-31 | $948.49 Million | $250.19 Million | 0.264x | +10.22% |
| 2010-12-31 | $883.89 Million | $211.53 Million | 0.239x | +56.71% |
| 2009-12-31 | $653.01 Million | $99.72 Million | 0.153x | +257.60% |
| 2008-12-31 | $507.70 Million | $-49.20 Million | -0.097x | -158.56% |
| 2007-12-31 | $295.79 Million | $48.95 Million | 0.165x | -31.44% |
| 2006-12-31 | $204.61 Million | $49.39 Million | 0.241x | +53.83% |
| 2005-12-31 | $275.10 Million | $43.17 Million | 0.157x | +44.72% |
| 2004-12-31 | $191.64 Million | $20.78 Million | 0.108x | +312.45% |
| 2003-12-31 | $167.76 Million | $-8.56 Million | -0.051x | +60.64% |
| 2002-12-31 | $171.66 Million | $-22.26 Million | -0.130x | +34.53% |
| 2001-12-31 | $196.40 Million | $-38.90 Million | -0.198x | -49.42% |
| 2000-12-31 | $234.74 Million | $-31.11 Million | -0.133x | +70.02% |
| 1999-12-31 | $53.60 Million | $-23.70 Million | -0.442x | +23.08% |
| 1998-12-31 | $16.70 Million | $-9.60 Million | -0.575x | -- |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil)… Read more